on year to date results in Q4, we estimate that GSK needs approximately $260,000,000 in sales for us to achieve the $25,000,000 milestone and approximately $610,000,000 in sales to achieve the $50,000,000 milestone. To put the $610,000,000 requirement into perspective, this is $240,000,000 or approximately 30% less than the consensus estimate of $850,000,000 We believe the recent performance for Telgy bodes well not just for the 2024 milestones, but also for the $150,000,000 of additional milestones we could achieve in 20252026, where consensus estimates are significantly higher than the sales required to achieve the full $150,000,000 of milestones. Given we are in a position to earn a milestone in 2024, I'd like to remind investors that achieving these milestones is tied to Royalty Pharma's receipt of Trelegy royalties from GSK. In order to make it easier for investors to track, we have provided an estimate of what net sales would need to be in order for these royalty thresholds to be met. For example, should 2024 net sales exceed $3,200,000,000 we estimate that GSK would pay Royalty Pharma $275,000,000 in royalties, which would trigger the $50,000,000 milestone to Theravance.